MetaCap

InspireMD Inc. (NSPR)

NASDAQ: NSPRHealth CareMedical/Dental InstrumentsUSD

0.54-0.0805 (-12.97%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

NSPR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$29.23M
EPS (TTM)
-$0.57
52-week range
0.43 – 2.17
Day range
0.4999 – 0.63
Volume / Avg
633.90K / 234.68K
Beta
—

52-week range

$0.43$2.17

NSPR stock today

On Nov 20, NSPR ended the session at $0.54, shedding $0.0805 (12.97%), versus the S&P 500's 3.70% decline. Volume was 2.7x the average at 633.90K shares, a sign of unusually heavy trading. Shares are 75.1% below their 52-week high of $2.17, set on Dec 23, 2025 and 25.6% above the 52-week low of $0.43, near the bottom of the past year's range.

NSPR is down 69.7% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 72.0%. InspireMD has posted a net loss over the last twelve months (EPS of -$0.57), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About InspireMD

Company profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid Stent System; and SwitchGuard neuroprotection system to provide flow reversal of cerebral protection in carotid interventions, as well as treating acute stroke with tandem lesions. The company was founded in 2005 and is headquartered in Miami, Florida.

Industry
Medical/Dental Instruments
CEO
Mr. Marvin L. Slosman
Headquarters
Miami, FL
Employees
127

Financial highlights

Full financials

In fiscal 2025, InspireMD generated $9.0 million in revenue, up 28.1% from fiscal 2024, its 5th consecutive year of revenue growth. InspireMD reported a net loss of $48.8 million, compared with a loss of $32.0 million a year earlier. Gross margin was 29.5% (up from 21.5%) and operating margin -552.6%.

InspireMD annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$8.98M$7.01M$6.21M$5.17M$4.50M
Growth+28.11%+12.96%+20.00%+15.04%+80.89%
Net income$-48.79M$-32.01M$-19.92M$-18.49M$-14.92M
EPS (diluted)$-0.76$-0.76$-0.82$-2.35$-2.03

Analyst forecast

Forecast

Consensus (3 analysts)

none

Avg. price target

$3.33+516.67%

  • Strong buy 2
  • Buy 1
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $3.00High $4.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.17 vs $-0.15
Surprise
-13.33%

NSPR news

All NSPR news

InspireMD peers

Health Care sector
NSPR peer companies
CompanyPrice% ChgMarket capCompare
XTNTXtant Medical Holdings Inc.0.21-2.82%$29.49Mvs NSPR
NEPHNephros Inc.2.61-8.10%$28.37Mvs NSPR
TELATELA Bio Inc.0.6885-5.27%$31.11Mvs NSPR
MDAISpectral AI Inc. Class A1.04-20.61%$33.47Mvs NSPR
PLRZPolyrizon Ltd.9.31-8.42%$22.61Mvs NSPR
DAVIDavion Healthcare Plc0.9001-9.99%$22.50Mvs NSPR
SRTSSensus Healthcare Inc.2.26-4.24%$37.20Mvs NSPR
PMIPicard Medical Inc.6.79+7.78%$18.07Mvs NSPR

Indexes, lists and sector

InspireMD stock FAQ

What is InspireMD's stock price today?

NSPR last traded at $0.54 as of Nov 20, 4:00 PM EST, down 12.97% on the day. Prices are delayed at least 15 minutes.

Does InspireMD pay a dividend?

No. InspireMD does not currently pay a regular cash dividend.

Who is InspireMD's CEO?

Mr. Marvin L. Slosman is the chief executive officer of InspireMD Inc., which has about 127 employees.

Has NSPR ever split its stock?

Yes. The most recent NSPR stock split was a 1-for-15 split on Apr 27, 2021, one of 5 splits on record.

What is the NSPR 52-week high?

The 52-week high for NSPR is $2.17 and the 52-week low is $0.43. The stock is currently 75.1% below its high.

Compare NSPR